Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2019 07:00 ET | Source: InflaRx N.V.

InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa

Retrospective long-term results from phase IIa trial indicate sustained remission post IFX-1 treatmentBaseline characteristics from ongoing phase IIb SHINE trial in line with expectations; on track...
January 03, 2019 08:30 ET | Source: InflaRx N.V.

InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management

Jason Marks appointed Chief Legal Officer / General CounselJordan Silverstein appointed Head of Corporate Strategy / Development JENA, Germany and NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) --...
December 19, 2018 08:30 ET | Source: InflaRx N.V.

InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis

JENA, Germany, Dec. 19, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting...
November 21, 2018 08:30 ET | Source: InflaRx N.V.

InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results

Completion of patient recruitment in phase IIb trial in Hidradenitis SuppurativaFirst patient dosed in phase II trial with IFX-1 in ANCA-associated vasculitis Board of Directors appointment Jens...
November 08, 2018 02:30 ET | Source: InflaRx N.V.

InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa

Trial Results Anticipated First Half 2019 JENA, Germany, Nov. 08, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat...
October 30, 2018 07:30 ET | Source: InflaRx N.V.

InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing

JENA, Germany, Oct. 30, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting...
September 21, 2018 08:30 ET | Source: InflaRx N.V.

InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors

JENA, Germany, Sept. 21, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening and devastating inflammatory...
August 28, 2018 07:30 ET | Source: InflaRx N.V.

InflaRx N.V. To Host R&D Day on Hidradenitis Suppurativa and its Breakthrough Anti-C5a Monoclonal Antibody IFX-1

Live webcast on Friday, September 7, 2018, 7.45-9.30 am EDT (1.45-3.30 pm CET) JENA, Germany, Aug. 28, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing...
August 09, 2018 07:00 ET | Source: InflaRx N.V.

InflaRx N.V. Reports Second Quarter 2018 Financial & Operating Results

Received FDA clearance of IND for Phase II trial of IFX-1 in ANCA-associated vasculitisEstablished U.S. research facility to continue advancing complement-based researchCompletion of follow-on...
June 28, 2018 07:30 ET | Source: InflaRx N.V.

InflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis

JENA, Germany, June 28, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory diseases by...